



Challenging Science. Changing Lives.

Lehman Brothers Tenth Annual Global Healthcare Conference

Mark G. Foletta

Sr. Vice President, Finance and Chief Financial Officer

Amylin Pharmaceuticals, Inc.

March 19, 2007

Safe Harbor Statement

This presentation contains forward-looking statements about Amylin. Our actual results could differ materially from those discussed due to a number of factors, including risks that BYETTA and/or SYMLIN may be affected by competition, unexpected new data, technical issues, or manufacturing and supply issues; our financial results may fluctuate and may not meet market expectations; our clinical trials may not start when planned and/or confirm previous results; our pre-clinical studies may not be predictive; our product candidates may not receive regulatory approval; our label expansion requests may not be submitted timely or receive regulatory approval; we may not be able to complete our manufacturing facility on a timely basis; and inherent scientific, regulatory and other risks in the drug development and commercialization process. Reimbursement and pricing decisions may also affect the potential of BYETTA and/or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-K. Amylin disclaims any obligation to update these forward-looking statements.


Building Sustainable Growth for the Future

- > Rapid growth of BYETTA and SYMLIN
- > Significant upside with growing market and expanded opportunity
- > Exenatide LAR: great progress – on track
- > Novel science, innovative approach to obesity research
 - > Four studies ongoing
- > Executing as planned and building for the future

Diabetes: Large and Growing Market

Vast opportunity for improved therapies

- > 15MM diagnosed in US
- > Growing at 2-3X the population rate
- > ~90-95% are type 2
 - > Over two-thirds are not at goal
 - > More than 80% are overweight





AMYLIN™

Challenging Science. Changing Lives.

Byetta®
exenatide injection

BYETTA

Improving glycemic control and losing weight

- > High adoption by diabetes specialists – over 85% have Rx'd
- > Rapid growth in use among Primary Care Physicians
- > \$430MM in sales for FY06



Expanding BYETTA Opportunities

- > Clinical development expanding market opportunity
 - > Room temperature storage – new instructions now in place
 - > New indication: ~3MM people on TZDs
 - > Monotherapy indication – study results expected by end '07
- > EU launches planned
 - > Beginning mid 2007
- > Reimbursement – increasing access to patients
 - > Over 80% of MCO lives have unrestricted access (tier 2 and tier 3)
 - > Broad access in Medicaid



AMYLIN™

Challenging Science. Changing Lives.



Symlin®
(pramlintide acetate)
injection


SYMLIN

Recognized partner hormone to insulin

- > SYMLIN – demonstrated value in treating diabetes
 - > Universal awareness and increasing use by endocrinologists
 - > Over 50,000 patients since launch
 - > \$44MM in sales for FY06
- > Opportunities for expansion
 - > Pen delivery system
 - > New indication for mealtime SYMLIN with basal insulin



Multiple Opportunities for Expansion Across the Diabetes Spectrum



Current market
~6 million on MET +/- SFU
~3 million using TZDs

**Potential expanded indication
as foundational diabetes therapy**




Current market
~1.3 million

Potential expanded indication
~1.2 million

Once-Weekly Exenatide LAR


Medisorb[®]: Mechanism of Drug Release



Once-Weekly Exenatide LAR

Results at 15 weeks – A1C and weight improvements

A1C Change (%)



Weight Change (lbs)



Clinical Study Enrollment Complete

On track to report study data in 4Q07


- > Enrollment completed 1Q07
- > 30-week, open-label, randomized study of ~300 subjects
 - > Includes BYETTA twice-daily comparator group
- > Efficacy endpoint – reduction in A1C
- > Once-weekly administration
- > Study product form: self administered, subcutaneous injection
 - > Finalizing product form with scale up
 - > Small injection volume
- > All patients on LAR in extension study

Manufacturing On Track

- > Completed scale-up to intermediate batch size
 - > Now used in the on-going clinical study
- > Commercial scale process successful in engineering runs
 - > Third party facility
- > Ohio mfg facility on track to be completed in 2008
- > Finalization of commercial process on track for 2H08

Overview of Products and Pipeline

Metabolic Solutions




Amylin: Foundation for INTO Strategy


- > Pramlintide is amylinomimetic with demonstrated weight effects:
 - > Efficacy – sustained 52-week weight loss in conjunction with lifestyle intervention
 - > Safety – approved for diabetes indication
- > Potential to become first neurohormonal therapy for obesity

Weight Loss Demonstrated with Pramlintide

360 mcg BID Regimen



120 mcg TID Regimen




—●— Placebo (n=17)

—▼— 360 mcg (BID n=22)

—■— 120 mcg (TID n=25)

Multiple Milestones in 2007



* Integrated Neurohormonal Therapy for Obesity

Amylin Pharmaceuticals

Building sustainable growth for the future

- > Rapid growth of BYETTA and SYMLIN
- > Significant upside with growing market and expanded opportunity
- > Exenatide LAR: great progress – on track
- > Novel science, innovative approach to obesity research
 - > Four studies ongoing
- > Executing as planned and building for the future